FDA approves Keytruda's new indications for treatment of Meckel cell carcinoma

recently, the U.SFDA(http://accelerated the approval of PD-1 tumor immunotherapy Keytruda (Chinese commodity name: Corida, generic name: Pablo Zumat) and a new indication for the treatment of recurrent late-stage or metastatic merincara (Cell carcinoma, MCC)the cITN-09/KEYNOTE-017it is understood that the accelerated approval is based on the results of a trial(http://called Phase II CITN-09/KEYNOTE-01
7, in which patients with advanced conditions who have not previously received systemic therapy In the trial, 50 patients with recurrent prestage or metastatic stage of metastatic cell carcinoma were treated every three weeks, and the overall condition of the subjects was poor, first of all older, 80 percent of patients over 65 years of age, and 86 percent of patients with distant metastasisfinal results show that Keytruda had an objective remission rate of 56 percent, including a full remission rate of 24 percent, a partial remission rate of 32 percent, and a stable 10 percent of patients with a total disease control rate of 66 percentAt the median follow-up of 14.9 months, 96% of the 28 patients who received remission lasted more than 6 months and 54% lasted more than 12 monthslast month, the FDA approved its PD-1 tumor immunotherapy Keytruda for the treatment of patients with hepatocellular cancer (HCC) who had previously been treated with the targeteddrug(http://sorafenib (Sorafenib); The FDA also approved Keytruda's combination chemotherapy (caplatinum-purple alcohol or albumin-combined yew alcohol (nab-paclitaxel)) for first-line treatment for patients with metastatic squamous NSCLC, regardless of their tumor PD-L1 expression statusthis approval, making Keytruda the first first-line treatment of scaly NSCLC regardless of tumor PD-L1 expression status pD-1 tumor immunotherapy